Regeneron Pharmaceuticals, Inc. REGN
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 17.29% | 19.31% | |||
| Total Other Revenue | 60.37% | 12.91% | |||
| Total Revenue | 19.23% | 19.01% | |||
| Cost of Revenue | 7.26% | -0.22% | |||
| Gross Profit | 31.93% | 49.56% | |||
| SG&A Expenses | 2.37% | 2.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.13% | 0.34% | |||
| Operating Income | 45.70% | 90.72% | |||
| Income Before Tax | 49.50% | 83.81% | |||
| Income Tax Expenses | 45.26% | 122.02% | |||
| Earnings from Continuing Operations | 50.26% | 78.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 50.26% | 78.34% | |||
| EBIT | 45.70% | 90.72% | |||
| EBITDA | 41.87% | 77.90% | |||
| EPS Basic | 51.88% | 80.42% | |||
| Normalized Basic EPS | 42.48% | 77.46% | |||
| EPS Diluted | 50.86% | 81.19% | |||
| Normalized Diluted EPS | 41.49% | 78.22% | |||
| Average Basic Shares Outstanding | -1.07% | -1.15% | |||
| Average Diluted Shares Outstanding | -0.38% | -1.58% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | -0.34% | -0.45% | |||